TY - JOUR
T1 - Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery
T2 - Otologists’ Perspective from Bedside to Bench
AU - Hosoya, Makoto
AU - Wakabayashi, Takeshi
AU - Wasano, Koichiro
AU - Nishiyama, Takanori
AU - Tsuzuki, Nobuyoshi
AU - Oishi, Naoki
N1 - Funding Information:
Funding: This research was supported by AMED under Grant Number JP20dk0310105, and by a grant from the Japanese government, MEXT KAKENHI (Grant-in-Aid for Scientific Research (C) 21K09565).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - Vestibular schwannoma is a clinically benign schwannoma that arises from the vestibulocochlear nerve that causes sensorineural hearing loss. This tumor is clinically and oncologically regarded as a benign tumor as it does not metastasize or invade surrounding tissues. Despite being a benign tumor, its management is difficult and controversial due to the potential serious complications, such as irreversible sensorineural hearing loss, of current interventions. Therefore, preventing hearing loss due to the natural course of the disease and complications of surgery is a challenging issue for an otologist. Improvements have been reported recently in the treatment of vestibular schwannomas. These include advances in intraoperative monitoring systems for vestibular schwannoma surgery where the risk of hearing loss as a complication is decreased. Precise genomic analysis of the tumor would be helpful in determining the characteristics of the tumor for each patient, leading to a better hearing prognosis. These procedures are expected to help improve the treatment of vestibular schwannomas. This review summarizes recent advances in vestibular schwannoma management and treatment, especially in hearing preservation. In addition, recent advances in the understanding of the molecular mechanisms underlying vestibular schwannomas and how these advances can be applied in clinical practice are outlined and discussed, respectively. Moreover, the future directions from the bedside to the bench side are presented from the perspective of otologists.
AB - Vestibular schwannoma is a clinically benign schwannoma that arises from the vestibulocochlear nerve that causes sensorineural hearing loss. This tumor is clinically and oncologically regarded as a benign tumor as it does not metastasize or invade surrounding tissues. Despite being a benign tumor, its management is difficult and controversial due to the potential serious complications, such as irreversible sensorineural hearing loss, of current interventions. Therefore, preventing hearing loss due to the natural course of the disease and complications of surgery is a challenging issue for an otologist. Improvements have been reported recently in the treatment of vestibular schwannomas. These include advances in intraoperative monitoring systems for vestibular schwannoma surgery where the risk of hearing loss as a complication is decreased. Precise genomic analysis of the tumor would be helpful in determining the characteristics of the tumor for each patient, leading to a better hearing prognosis. These procedures are expected to help improve the treatment of vestibular schwannomas. This review summarizes recent advances in vestibular schwannoma management and treatment, especially in hearing preservation. In addition, recent advances in the understanding of the molecular mechanisms underlying vestibular schwannomas and how these advances can be applied in clinical practice are outlined and discussed, respectively. Moreover, the future directions from the bedside to the bench side are presented from the perspective of otologists.
KW - NF2 gene
KW - hearing loss
KW - hearing preservation surgery
KW - vestibular schwannoma
UR - http://www.scopus.com/inward/record.url?scp=85129371992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129371992&partnerID=8YFLogxK
U2 - 10.3390/diagnostics12051044
DO - 10.3390/diagnostics12051044
M3 - Review article
AN - SCOPUS:85129371992
SN - 2075-4418
VL - 12
JO - Diagnostics
JF - Diagnostics
IS - 5
M1 - 1044
ER -